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Abstract: Topical 5% lidocaine medicated plasters represent a well-established first-line 
option for the treatment of peripheral localized neuropathic pain (LNP). This review provides 
an updated overview of the clinical evidence (randomized, controlled, and open-label clinical 
studies, real-life daily clinical practice, and case series). The 5% lidocaine medicated plaster 
effectively provides pain relief in postherpetic neuralgia, and data from a large open-label 
controlled study indicate that the 5% lidocaine medicated plaster is as effective as systemic 
pregabalin in postherpetic neuralgia and painful diabetic polyneuropathy but with an improved 
tolerability profile. Additionally, improved analgesia and fewer side effects were experienced by 
patients treated synchronously with the 5% lidocaine medicated plaster, further demonstrating the 
value of multimodal analgesia in LNP. The 5% lidocaine medicated plaster provides continued 
benefit after long-term (#7 years) use and is also effective in various other LNP conditions. 
Minor application-site reactions are the most common adverse events associated with the 5% 
lidocaine medicated plaster; there is minimal risk of systemic adverse events and drug–drug 
interactions. Although further well-controlled studies are warranted, the 5% lidocaine medicated 
plaster is efficacious and safe in LNP and may have particular clinical benefit in elderly and/or 
medically compromised patients because of the low incidence of adverse events.
Keywords: 5% lidocaine medicated plaster, clinical evidence, localized neuropathic pain, 
postherpetic neuralgia, review
Introduction
Neuropathic pain, one of the underlying causes of chronic pain, may result from a lesion 
or a disease of the somatosensory system.1 Depending on the site of the lesion within 
the nervous system, the origin of neuropathic pain can be either central or peripheral.2,3 
Although prevalence estimates vary, neuropathic pain is reported to affect up to ∼18% 
of the population in developed countries,4 with up to ∼60% of patients presenting with 
localized symptoms (localized neuropathic pain [LNP]).5,6 Based on the International 
Association for the Study of Pain definition of neuropathic pain, LNP is defined as 
a type of neuropathic pain that is “characterized by consistent and circumscribed 
area(s) of maximum pain associated with negative or positive sensory signs and/or 
spontaneous symptoms characteristic of neuropathic pain”.7 Common LNP conditions, 
predominantly occurring in elderly individuals, include postherpetic neuralgia (PHN), 
diabetic polyneuropathy (DPN), and neuropathic postoperative pain.2,8–10 Neuropathic 
pain conditions can be debilitating, with a serious negative impact on patient function-
ing, daily activities, and overall quality of life (QoL).11,12
The management of neuropathic pain is complex and multidisciplinary, requiring 
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the pharmacological options available for optimal pain 
management, and the individual needs of the patient (eg, 
elderly, receiving multiple medications).13 Nevertheless, 
despite the availability of numerous management guidelines, 
many patients do not receive adequate pain management, and 
many are not satisfied with their treatment.13 Pharmacological 
treatment options include the topical 5% lidocaine medicated 
plaster, tricyclic antidepressants, serotonin–norepinephrine 
reuptake inhibitors, gabapentin and pregabalin, and 
opioids.8,13–15
As discussed previously,14 the 5% lidocaine medicated 
plaster (a 10 cm×14 cm adhesive plaster, containing 700 mg 
[5% w/w] lidocaine; Versatis®, Grünenthal) has a dual mode 
of action by providing a mechanical barrier effect and a 
pharmacological action via voltage-gated sodium channel 
blockade as a direct result of lidocaine action.
Numerous reviews and clinical guidelines recommend the 
topical 5% lidocaine medicated plaster as a first-line option 
for LNP,16–28 with the majority of clinical evidence available 
for patients with PHN. However, due to differences in data 
analysis and without significant changes in the available data 
in the last 5 years (see “Discussion” section), recommenda-
tions are not always aligned.29 The topical 5% lidocaine 
medicated plaster is approved in ∼50 countries worldwide for 
the symptomatic relief of neuropathic pain associated with 
previous herpes zoster infection; in nine of these countries, 
it is also approved for the treatment of LNP. It is estimated 
that, since the first marketing approval in 1999 and up to June 
2014, the topical 5% lidocaine medicated plaster has been 
prescribed to ∼20 million patients worldwide.30
This article presents an updated narrative appraisal of 
the clinical evidence (efficacy and safety in clinical trials, 
in addition to extensive experience gained in daily clinical 
practice) with the topical 5% lidocaine medicated plaster 
in LNP, focusing primarily on its use in patients with PHN 
and DPN and presenting a brief overview of recent evidence 
in other LNP conditions. In order to provide a reappraisal 
of the clinical evidence for the use of the 5% lidocaine 
medicated plaster in the treatment of LNP conditions, all 
efficacy and safety studies (randomized, controlled, or open 
label with a well-described methodology), case reports, and 
observational studies on the 5% lidocaine medicated plaster 
were retrieved from a PubMed literature search (1960 to 
September 30, 2015). Additional references were identi-
fied from the reference lists of published articles. Search 
terms were “lidocaine” and (“patch” or “topical”) or “lido-
caine medicated plaster”. Inclusion of studies was based 
mainly on the methods section of the trials. If available, 
large, well-controlled trials with appropriate statistical 
methodology were preferred.
Clinical evidence with the topical 5% 
lidocaine medicated plaster in LNP
PHN or painful DPN
PHN is the most common chronic complication of the reac-
tivation of the herpes zoster virus that results in shingles, 
manifesting as LNP, with ∼20% of patients with herpes zoster 
reporting some pain at 3 months after the onset of symptoms. 
The frequencies of herpes zoster infection and PHN increase 
with age.9 Painful DPN, a common chronic complication that 
occurs in up to ∼20% of patients with diabetes, is associated 
with a significant negative impact on the patient’s QoL31–33
Several articles have previously reviewed clinical trials 
in which the topical 5% lidocaine medicated plaster was 
administered to patients with localized PHN14,27,34 or DPN.14,35 
An overview of topical 5% lidocaine medicated plaster clini-
cal trials is provided here for completeness, in addition to 
a review of more recent experience gained in daily clinical 
practice and in long-term studies.
One of the earliest clinical trials to demonstrate the 
efficacy of the 5% lidocaine medicated plaster was a four-
session (12 hours each session), randomized, double-blind, 
vehicle-controlled study in 35 patients with established PHN 
affecting the torso or extremities.36 Lidocaine plasters were 
applied in two of the four sessions, a vehicle plaster in one 
session, and the remaining session was a no-treatment obser-
vation session. Compared with no-treatment observation, 5% 
lidocaine medicated plasters significantly (P,0.05) reduced 
pain intensity at each time point (from 30 minutes to 12 hours 
and from 4 to 12 hours) compared with vehicle plasters. Lido-
caine plasters were superior to both no-treatment observation 
(P,0.0001) and vehicle (P=0.033) in mean category pain 
relief scores. Minimal systemic absorption of lidocaine was 
observed (maximum blood lidocaine level 0.1 µg/mL). No 
systemic side effects were reported.36
Two clinical studies used a randomized, withdrawal 
(enriched enrollment) design.37,38 In the study by Galer 
et al,37 patients had been treated successfully with topical 
5% lidocaine medicated plasters on a regular basis for at 
least 1 month before study enrollment. Subjects were sub-
sequently enrolled in a randomized, two-treatment period, 
vehicle-controlled, crossover study. The primary efficacy 
variable was “time to exit” due to a lack of efficacy (defined 
as a decrease in pain relief score by two or more categories 
on a six-item pain relief scale for any 2 consecutive days). 
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significantly greater than with the vehicle plaster (.14 days 
vs 3.8 days, P,0.001). At study completion, significantly 
more patients expressed a preference for the lidocaine plaster 
than the vehicle plaster (78.1% vs 9.4%, P,0.001). There 
were no statistically significant between-group differences 
with regard to side effects.37
The study by Binder et al,38 a double-blind, placebo 
plaster-controlled, parallel group study, was conducted at 33 
outpatient centers in 12 European countries between April 
2003 and June 2004. Patients aged $50 years with PHN and 
neuropathic pain persisting $3 months postrash healing and 
mean pain intensity of $4 on the 11-point numerical rat-
ing scale (NRS-11) were enrolled in an 8-week open-label, 
active treatment (5% lidocaine medicated plaster) run-in 
phase. Responders entered a 2-week, double-blind phase and 
were randomized to the 5% lidocaine medicated plaster or a 
placebo plaster. Patients applied up to three plasters for up 
to 12 hours/day. The primary endpoint was time to exit due 
to a $2-point reduction in pain relief on 2 consecutive days 
of plaster application using a six-item verbal rating scale. 
Among the 263 patients entering the initial 8-week run-in 
phase, 51.7% (n=137) achieved at least moderate pain relief 
on active treatment (responders). Seventy-one responders 
completed the entire 8-week initial phase and subsequently 
entered the double-blind phase and were randomized to the 
5% lidocaine medicated plaster (n=36) or a placebo plaster 
(n=35). Median time to exit was numerically longer for the 
5% lidocaine medicated plaster than the placebo plaster group 
(13.5 [range: 2–14] vs 9.0 [range: 1–14] days, P=0.151). For 
per-protocol patients (n=34), median time to exit was signifi-
cantly longer in the 5% lidocaine medicated plaster than the 
placebo plaster group (14.0 [range: 3–14] vs 6.0 [range: 1–14] 
days, P=0.0398). During the 8-week run-in phase, treatment 
with the 5% lidocaine medicated plaster was associated with 
clinically relevant improvements in extremely painful and 
painful allodynia, QoL, and sleep measures, particularly in 
patients identified as responders.38
The 5% lidocaine medicated plaster reduced pain inten-
sity in patients with PHN with impaired nociceptor function 
(determined by heat pain thresholds and histamine-induced 
flare)39 but not in those with preserved function in a random-
ized, double-blind, placebo-controlled substudy in 40 patients 
from a larger study in patients with any focal neuropathic 
pain.40
Recently, Casale et al41 reported data from a retrospective 
case review of eight patients with PHN who received the 5% 
lidocaine medicated plaster. The study cohort comprised 
mainly elderly patients taking multiple drugs (a mean of four 
± two nonanalgesic drugs) to treat comorbidities, representing 
a population that is at a high risk of drug–drug interactions. 
Good pain relief (of at least 30%) was observed during a 
3-month follow-up period, and pain relief was associated with 
a 46% reduction in the size of the painful area after 1 month 
(from 236.38±140.34 to 128.80±95.7 cm2) and a 66% reduc-
tion after 3 months (to 81.38±59.19 cm2). Although these 
observations confirm the effectiveness of the 5% lidocaine 
medicated plasters in the treatment of PHN, the authors of 
this study also noted that reduction in the size of the painful 
area represents a possible additional clinical benefit of the 
5% lidocaine medicated plaster that warrants confirmation 
in large randomized controlled clinical trials.41 This outcome 
was also reported in a prospective, observational study of 
19 patients with traumatic injuries to peripheral nerves that 
were accompanied by LNP of .3 months duration.42 The 
5% lidocaine medicated plaster effectively reduced both 
pain intensity and the size of the painful area, and no local 
or systemic adverse effects were reported.42 This observation 
has significant neurobiological implications as it suggests 
that long-term treatment may be associated with a reversal 
of central sensitization, as judged by the reduction in the 
receptive field zone.43
Painful DPN
As overviewed in Table 1, the effectiveness and safety of the 
5% lidocaine medicated plaster have been evaluated in several 
open-label studies in patients with DPN,44–48 some of which 
also included patients with PHN44,46–48 or low back pain.44,46
The comparative efficacy and tolerability of the 5% 
lidocaine medicated plaster and pregabalin were evaluated 
in one study (discussed in more detail later).47 In the study 
that enrolled only patients with clinically defined painful 
DPN of .3 months’ duration, significant improvements 
in pain and QoL outcomes were observed after 3 weeks of 
treatment with up to four 5% lidocaine medicated plasters 
daily for 18 hours.45 Patients received the 5% lidocaine 
medicated plaster as add-on therapy to a stable analgesic 
regimen. The mean daily pain rating (using the Brief Pain 
Inventory [primary outcome]) reduced from 6.3±1.5 (base-
line) to 3.6±2.1 (week 3; P#0.001). Significant improve-
ments were also observed from baseline to week 3 in sleep 
quality (26.9 vs 59.6; P#0.001), all individual aspects and 
the overall summary score of pain interference assessed 
by the Brief Pain Inventory (summary score: 32.1±15.6 vs 
20.3±16.2; P#0.001), Beck Depression Inventory scores 
(10.5±6.7 vs 7.2±5.7; P#0.001), and the Profile of Mood 
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5% lidocaine medicated plaster in LNP
depression–dejection (7.3±8.5 vs 4.7±6.3; P#0.01), anger–
hostility (5.6±7.0 vs 4.0±6.0; P#0.05), fatigue–inertia 
(11.0±6.7 vs 8.4±6.7; P#0.001), and total mood disturbance 
(44.6±24.6 vs 35.2±19.1; P#0.001) scales. Improvements 
were maintained for up to a total of 8 weeks in a subgroup 
of patients (tapering of concomitant analgesic therapy was 
permitted during the 5-week extension phase). There was no 
systemic accumulation of lidocaine, and adverse events were 
minimal (mostly minor application-site events).45
A systematic review and meta-analysis of the 5% lido-
caine medicated plaster in patients with DPN indicated that 
the effects of the 5% lidocaine medicated plaster on pain 
reduction are comparable to those of amitriptyline, capsai-
cin, gabapentin, and pregabalin.35 In the meta-analysis, all 
interventions remained effective compared with placebo 
(mean difference in change of pain from baseline compared 
with placebo, amitriptyline: −12.58 [95% confidence interval 
{CI}, −16.66 to −8.50]; capsaicin: –9.40 [95% CI, −13.92 
to −4.88]; gabapentin: −10.22 [95% CI, −17.25 to −3.19]; 
pregabalin: −10.53 [95% CI, −14.74 to −6.32]; 5% lidocaine 
medicated plaster: −9.10 [95% CI, −13.93 to −4.26]), and 
the 5% lidocaine medicated plaster was comparable to all 
other interventions (amitriptyline: 3.48 [95% CI, −0.78 to 
7.75]; capsaicin: 0.31 [95% CI, −4.39 to 5.00]; gabapentin: 
1.12 [95% CI, −6.02 to 8.27]; and pregabalin: 1.43 [95% CI, 
−2.96 to 5.83]). The authors concluded that topical agents 
such as the 5% lidocaine medicated plaster may be associated 
with fewer and less clinically significant adverse events than 
is the case for systemic agents. However, the results of the 
systematic review were limited by the number and size of 
studies included, warranting further well-designed studies in 
this patient population.35
Compared with pregabalin
The 5% lidocaine medicated plaster has been compared with 
pregabalin in an open-label trial in patients with PHN (n=96) 
or painful DPN (n=204).47,49 At baseline, patients had a mean 
pain intensity score of 6.75 on the 11-point NRS during the 
previous 3 days (NRS-3). Patients received the topical 5% 
lidocaine medicated plaster (applied to the most painful skin 
area) or twice-daily pregabalin capsules (150−600 mg/d 
titrated to effect) in a 1:1 ratio at 51 European centers in this 
two-stage, randomized, open-label, multicenter, noninferior-
ity study. During the initial 4-week comparative stage, the 
response rate (average reduction from baseline of $2 points 
or an absolute value of #4 points on the NRS-3) in the full 
analysis set (all randomized patients who received at least 
one dose of the investigational products and for whom at 
least one postbaseline assessment of pain intensity [NRS-3] 
was available) was 66.4% (101/152) with the 5% lidocaine 
medicated plaster and 61.5% (91/148) with pregabalin, indi-
cating noninferiority of the 5% lidocaine medicated plaster 
to pregabalin (P=0.00229). When the results were analyzed 
by indication, more patients in the PHN group responded to 
the 5% lidocaine medicated plaster than to pregabalin treat-
ment (63.3% vs 46.8%; statistical data not reported), while 
in the painful DPN group, the between-treatment response 
was comparable (68.0% vs 68.3%).
Among the secondary end points, $30% (57.8% vs 
48.8%) and $50% (35.6% vs 20.9%) reductions in NRS-3 
scores were greater with the 5% lidocaine medicated plaster 
than with pregabalin in patients with PHN but not in patients 
with DPN ([59.6% vs 56.4%] and [40.4% vs 37.2%]). Despite 
greater baseline values in patients with PHN than in those 
with painful DPN, reductions in the rates of “painful” and 
“extremely painful” allodynia were greater with the 5% 
lidocaine medicated plaster (57.8% at baseline to 25.0%) 
than with pregabalin (62.8%–41.2%) in patients with PHN; 
the between-treatment reduction in allodynia severity was 
comparable in patients with painful DPN. Significantly 
fewer patients using the lidocaine patch 5% experienced 
drug-related adverse events compared with those taking 
pregabalin (P,0.0001). Adverse events associated with the 
use of the 5% lidocaine medicated plaster were mainly mild-
to-moderate application-site reactions, whereas, in pregabalin 
recipients, adverse events mainly affected the central nervous 
system and were of moderate-to-severe intensity.47
in combination with pregabalin
The benefits of the 5% lidocaine medicated plaster in 
combination with pregabalin for 8 weeks were evaluated 
in patients with PHN or painful DPN48,50 who had an inad-
equate response to monotherapy for 4 weeks in the first 
phase of the comparative study.47,49 Patients continuing on 
monotherapy demonstrated additional decreases in NRS-3 
scores. However, patients receiving combination therapy 
achieved further mean reductions in NRS-3 scores, above 
those experienced during the initial 4 weeks of monotherapy.48 
These improvements were similar between patients who 
started with pregabalin and added 5% lidocaine medicated 
plaster (5.8±0.8 to 4.0±1.7; n=43) and those who initially 
received the 5% lidocaine medicated plaster and then added 
pregabalin (6.1±1.0 to 3.6±1.5; n=57). In a secondary 
analysis of only patients with PHN from the first phase of 
the comparative study who were unresponsive to either the 
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monotherapy, combination therapy provided additional effi-
cacy and was well tolerated.50 The results of these two studies 
give further support to the concept of multimodal analgesia51 
and suggest that patients treated this way can experience not 
only better analgesia but also less bothersome side effects 
that are frequently observed with high doses of pregabalin 
or gabapentin.
LNP of different etiologies
In addition to its efficacy and safety in PHN and DPN, the 5% 
lidocaine medicated plaster has been evaluated in a diverse 
range of other LNP conditions, including myofascial pain 
syndrome,52–54 burn sequelae in children,55 cervical radicu-
lopathy,56 inguinal postherniorrhaphy pain,57 postsurgical 
neuropathic pain in patients with cancer,58 cancer pain with 
neuropathic components or trigeminal neuropathic pain,59 
orofacial pain,60 persistent postmastectomy pain,61 and 
various other conditions62 (Table 2). Most reports indicate 
clinical benefits with the 5% lidocaine medicated plaster 
in various LNP conditions. However, two double-blind, 
placebo-controlled, crossover studies in patients with severe, 
persistent, inguinal postherniorrhaphy pain,57 or postsurgi-
cal neuropathic pain in patients with cancer,58 reported no 
significant benefit with the 5% lidocaine medicated plaster 
(Table 2). In studies where the safety of the 5% lidocaine 
medicated plasters was evaluated, a very low incidence of 
local or systemic adverse events was reported.
In daily clinical practice
In addition to the evidence gained in the clinical trial set-
ting, the use of the topical 5% lidocaine medicated plaster 
has been evaluated in the daily clinical practice setting in 
patients with LNP.63–68
In an effectiveness study performed at 42 US centers 
(large institutional primary care programs and academic 
centers, including pain centers, neurologists, and pain special-
ists affiliated with a university), the 5% lidocaine medicated 
plaster was associated with significant reductions from base-
line in all mean pain intensity and composite scores at each 
time point in 332 patients with PHN (P=0.0001). Overall, 
66% of patients reported improvements in pain intensity after 
7 days of treatment; ∼43% of patients who did not respond 
after 7 days experienced improvement in pain intensity after 
14 days of treatment.63 These findings suggest that when 
initiating therapy with the 5% lidocaine medicated plaster, 
a trial of at least 14 days should be implemented before cen-
soring patients as nonresponders. Moreover, if there is some 
degree of improvement, the plaster should not be removed, 
and other antineuropathic medications should be started to 
conform with the multimodal therapeutic approach in order 
to obtain adequate pain relief.20
The day-to-day clinical use of the topical 5% lidocaine 
medicated plaster was evaluated in a prospective, observa-
tional study as part of a compassionate use program in 625 
elderly patients (mean age 73.6 years) with PHN in France.64 
Treatment with the 5% lidocaine medicated plaster resulted 
in a significant quantitative reduction in concomitant neu-
ropathic pain treatments and associated side effects, while 
maintaining the quality of analgesia. The safety analysis 
showed that the 5% lidocaine medicated plaster was well 
tolerated, with the incidence of adverse events being 2.6% 
(n=16). Adverse events were mainly related to application-
site reactions, for which six patients discontinued treatment, 
and no events were considered serious.64
Another prospective, observational study evaluated 
patients’ perceptions of the topical 5% lidocaine medicated 
plaster in almost 1,000 patients with chronic neuropathic pain 
in daily clinical practice in Germany.65 In this patient popula-
tion, where 44.8% had PHN, patients perceived the 5% lido-
caine medicated plaster as an efficacious treatment of chronic 
neuropathic pain (mean pain intensity .24 hours improved 
by 5.1 points [74%] from 6.9±1.6 points at baseline, assessed 
using the NRS-11). The most notable treatment effects were 
in patients with PHN or DPN. A 30% reduction in overall pain 
intensity was observed within the first 2−3 weeks, with con-
tinuous further reductions until the end of the study. Marked 
improvements in anxiety and depression scores (40% and 
52%, respectively) and in pain-related restrictions in activities 
of daily living (66%) and QoL (157%) were also noted. The 
mean burden of pain (calculated on a 0−100 scale as the sum 
of three pain intensity scores [lowest, average, highest inten-
sity] plus modified pain disability index sum score plus [40 
minus QoL impairment by pain inventory sum score]) was 
reduced by 56.2 points (73%) from 77.5 points at baseline. 
Greatest pain relief and associated improvements in pain-
related restrictions were observed within the first 5 weeks 
of treatment; however, beneficial effects continued until the 
end of the 12-week observation period.65 Consequently, this 
study showed that the treatment of these individuals with 
5% lidocaine medicated plasters was associated with an 
improvement not only in the level of analgesia but also in 
anxiety, depression, and QoL measurements. This is a very 
important finding because the success of an analgesic therapy 
should not be assessed solely by the effects it has on pain 
but also on QoL variables. This was also the case in a study 
conducted within a large teaching hospital in the UK. Pain, 
functioning, and patient  satisfaction were improved signifi-
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Study type (number of 
patients)
Main outcomes
Myofascial pain syndrome (MPS)
 Dalpiaz and Dodds52 Single case report Pain threshold (P,0.001) and general activity (P,0.05) increased with LMP.
 Affaitati et al53 r, c (LMP, PL, or TPi)  
(n=60 [20 patients/group])
Subjective symptoms: no change from baseline (PL); decreased (LMP or TPi; P,0.001).  
Pain thresholds: no change from baseline (PL); increased (LMP or TPi; P,0.001). Additional  
treatment requested: only PL (P,0.001). No adverse events occurred in any group.
 Lin et al54 r, db, pr, pc (n=60): LMP  
(n=31), PL (n=29)
At day 14, pain intensity (using the vRS) decreased from baseline in the LMP group  
(1.06±0.79 vs 1.64±0.65); pain intensity was significantly greater in the PL group than in the  
LMP group at day 14 (1.50±0.76 vs 1.06±0.79; P=0.03).
Burn sequelae in children
 Orellana Silva et al55 pr, uc (n=14) Pain intensity (FACeS): 6.8±1.6 (initial), 0 (final) in 11 of 12 patients; (DN4): −6 (initial),  
−2.3 (final). All patients reported improved functionality. Plasma lidocaine levels: #27.45  
ng/mL (.180 times below critical levels). No adverse reactions occurred.
Cervical radiculopathy
 Mattozzi56 Retrospective chart  
review (n=60): LMP (n=30)  
or mesotherapy (n=30)
Both treatments (mesotherapy or LMP) were effective (quantitative data not reported).
Severe, persistent, inguinal postherniorrhaphy pain
 Bischoff et al57 r, db, pc, co (n=21) No difference in summed pain intensity differences between LMP and PL in all 21 patients  
(mean difference 6.2% [95% Ci =−6.6% to 18.9%]; P=0.33). Quantitative sensory testing  
demonstrated increased pressure pain thresholds after LMP compared with PL (P=0.007).
Postsurgical NP in cancer patients
 Cheville et al58 r, db, mc, pc, co (n=28) No significant intergroup differences were detected in pain intensity ratings. Individual  
BPi-SF scores for general activity (P=0.02), work (P=0.04), and relations with others  
(P=0.02) were lower with LMP than with PL.
Cancer pain with NP components or trigeminal NP
 Kern et al59 Retrospective case  
series (n=65 evaluable  
cases): cancer pain with  
NP components (n=41);  
trigeminal NP (n=24)
Cancer pain with NP components 
CGiC: very much improved (24.4%), much improved (48.8%), minimally improved (14.6%),  
no change (12.2%). 
Trigeminal NP 
CGiC: very much improved (16.7%), much improved (37.5%), minimally improved (16.7%),  
no change (25%), minimally worse (4.2%).
Orofacial pain
 Casale et al60 Single case report Pain intensity (0–10 cm vAS): .10 (baseline), 6.7 (LMP for 14 days). Reduced size of the  
painful area (quantitative data not reported). 
Quality of life (euroQol): 0.64 (baseline), 0.87 (LMP for 14 days).
Persistent postmastectomy pain





 Likar et al62 Retrospective case  
series (n=27 evaluable  
cases): dorsalgia  
(n=16); postoperative/ 
posttraumatic pain (n=7);  
both (n=1); phantom limb  
pain (n=1); PHN (n=1);  
unspecified (n=1)
During the 6-month observation period, overall mean pain intensity (NRS 0-10) decreased  
by 4.98 points to 3.5±2.6. Reductions were also observed for neuralgiform pain (5 points  
to 2.9±2.6 at baseline) and burning pain (3 points to 2.2±2.7). Mean sleep quality improved  
from 4.6±2.6 (baseline) to 5.5±1.8 (Likert scale 0 [worst possible sleep] to 10  
[best possible sleep]). LMP was well tolerated.
Abbreviations: BPi-SF, Brief Pain inventory-Short Form; c, controlled; CGiC, clinical global impression of change; co, crossover; db, double-blind; DN4, Douleur 
Neuropathique 4 pain-rating scale; FACeS, wong–Baker FACeS® pain-rating scale; LMP, 5% lidocaine medicated plaster; mc, multicenter; NP, neuropathic pain; NRS, 
numerical rating scale (0= not present, 10= worst possible state); pc, placebo-controlled; PHN, postherpetic neuralgia; PL, placebo; pr, prospective; r, randomized; TPi, trigger 
point infiltration; uc, uncontrolled; VAS, visual analog scale; VRS, verbal rating scale (0= no pain, 1= mild pain, 2= moderate pain, 3= severe pain, 4= very severe pain).
already receiving this form of therapy.67 Before using the 
plaster, the median pain score (assessed using the NRS-11) 
was 8 (interquartile range: 7−9). One month after therapy 
was started, pain decreased to a level of 6 of 10 in all patients 
and to 5 of 10 in those who were already receiving this 
form of therapy. Reductions were statistically significant 
(P,0.001 for both groups). The majority of current users 
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of functioning were significantly improved in current users: 
sleep (63.3% vs 20.1%, P,0.001), mood (59.2% vs 18.6%, 
P,0.001), and activity level (50.0% vs 19.5%, P,0.001). 
Median patient satisfaction scores (ranked from 0 [extremely 
dissatisfied] to 10 [extremely satisfied]) were 5 (interquartile 
range: 1−8) and 7 (5−9) in the overall population and current 
users, respectively.
Long-term use
Long-term use of the topical 5% lidocaine medicated plaster 
(for up to 5 years) has been evaluated in several clinical 
 trials69–71 and a .7-year follow-up survey.72 Furthermore, 
extensive long-term experience (.20 million patients) has 
been gained since the introduction of the 5% lidocaine medi-
cated plaster into numerous markets worldwide in 1999.30
The long-term treatment of neuropathic pain symptoms in 
patients with PHN was evaluated in a 12-month, open-label, 
noncomparative, phase III study conducted at 34 outpatient 
clinics in 12 European countries (247 evaluable patients).69 
Up to three 5% lidocaine medicated plasters were applied to 
the painful area for up to 12 hours each day, with a treatment-
free period of at least 12 hours required per day. Patients were 
permitted to continue receiving concomitant medication. 
In newly recruited patients (n=97), the mean average pain 
intensity (NRS-11) scores at baseline, week 12, and at the end 
of the 12-month study were 5.9±1.4, 3.9±1.6, and 3.9±2.3, 
respectively. Pain intensity also decreased from baseline 
(3.9±1.9) to study end (3.4±2.0) in pretreated patients (n=150; 
no statistical data reported). Pain relief values were consistent 
with reductions in pain intensity and were sustained in the 
long term. Overall, a total of 77.3% (191 of 247) of patients 
were classified as “improved” from baseline. Infections (eg, 
bronchitis and nasopharyngitis) were the most common 
adverse events. In total, 48 treatment-related adverse events 
(mainly mild-to-moderate administration-site disorders) 
occurred in 31 (12.4%) patients.69
A total of 102 patients (mean age 71 years, 64% female) 
continued from the main 12-month long-term study69 into 
an extension phase of up to 3 years (total of up to 4 years 
treatment with the 5% lidocaine medicated plasters).70 Mean 
pain relief of at least 4.3 on the six-point verbal rating scale, 
which had been achieved after 6 weeks in the initial 12-month 
phase of the study, was maintained throughout this 3-year 
extension period. At all visits, global impression of change, 
assessed by the investigator and patient using the clinical 
global impression of change and patient’s global impression 
of change questionnaires, respectively, were “much” or “very 
much” improved in ∼80% of patients. For global evaluation 
of the 5% lidocaine medicated plaster, clinicians and patients 
were asked how they rated the study medication at each visit – 
poor, fair, good, very good, and excellent. At the final visit, 
the 5% lidocaine medicated plaster was rated as “excellent”, 
“very good”, or “good” by 91% (67/74) of physicians and 
88% (67/76) of patients. Compared with the initial 12-month 
study, there was no increased frequency of treatment-related 
adverse events during the 3-year extension phase.70 These 
results indicate that the 5% lidocaine medicated plaster 
appears to provide effective long-term treatment of neuro-
pathic pain symptoms in patients with PHN without evidence 
of tolerance or tachyphylaxis.69,70
A retrospective, observational study investigated the 
efficacy and safety of the 5% lidocaine medicated plaster in 
431 evaluable patients (25.0% aged .70 years) with refrac-
tory chronic neuropathic pain who attended eleven pain 
centers in France over a 5-year time period.71 Treatment of 
refractory neuropathic pain with the 5% lidocaine medicated 
plaster clearly demonstrated efficacy and an excellent safety 
profile. The 5% lidocaine medicated plaster reduced pain 
intensity by .50% or $30% in 45.5% and 82.2% of patients, 
respectively. Statistically significant reductions in the use of 
analgesics (World Health Organization step I [13.2%], step II 
[23.7%], step III [9.1%,]; all P,0.0001) and coanalgesics 
for neuropathic pain (tricyclic antidepressants [14.9%, 
P,0.0001], antiepileptics [20.8%, P,0.0001], and serotonin 
reuptake inhibitors [4.9%, P=0.005]) were observed in the 
overall population, with even greater reductions in patients 
aged .70 years.71
Under a compassionate use agreement, 20 geriatric 
patients (mean age 75 years) who had used the topical 
5% lidocaine medicated plaster in clinical trials and were 
offered to continue therapy (mean duration 7.6 years [range: 
4−15 years]) completed a survey to assess effectiveness, 
tolerability, and patient satisfaction.72 Patients reported a 
high degree of satisfaction with long-term 5% lidocaine 
medicated plaster use as judged by overall satisfaction, 
comparison of efficacy with previous treatment, pain relief, 
dosing convenience, ability to perform normal daily activi-
ties, and tolerability.72
The long-term safety of the topical 5% lidocaine medi-
cated plaster has been reported in a pooled analysis of clinical 
trial data for 502 patients with PHN and from spontaneous 
safety reports from consumers and health-care professionals 
in ∼20 million patients (as of July 2014).15,30 In the majority 
of patients with adverse drug reactions, application-site ery-
thema and application-site pruritus were the most frequently 
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occurred.15 Moreover, based on postmarketing surveillance 
experience in ∼20 million patients worldwide, application-
site reactions or reports of a lack of drug efficacy were the 
majority of adverse events reported spontaneously, findings 
that concur with the safety profile identified during the clini-
cal development program.30
Effects on QoL
Improvements in QoL have been reported in several studies 
of the topical 5% lidocaine medicated plaster in patients 
with LNP.45,47,63
In an open-label effectiveness study, 249 of 332 patients 
with PHN reported improved QoL after treatment with the 5% 
lidocaine medicated plaster for 7 days, with further improve-
ments until the end of the study (28 days; P=0.0001). For all 
measures of pain intensity, pain relief, and interference with 
QoL, improvements from baseline were equally significant 
regardless of the time interval since the onset of shingles.63
In 300 evaluable patients with PHN (n=96) or painful 
DPN (n=204), the 5% lidocaine medicated plaster improved 
QoL (based on the EuroQol-5 dimension QoL index) to 
a greater extent than pregabalin.47 The mean change in 
EuroQol-5 dimension estimated health state score from 
baseline (all patients) was 0.12 and 0.04 in 5% lidocaine 
medicated plaster and pregabalin recipients, respectively.47 
Other measures of health-related QoL, Patient’s Global, 
and Clinical Global Impression of Change scores indicated 
greater improvements with the 5% lidocaine medicated 
plaster than pregabalin in the PHN group but not in the 
painful DPN group.47
The 5% lidocaine medicated plaster (maximum of four 
plasters daily for 18 hours) also significantly improved QoL 
ratings (sleep quality, pain interference, depression, and 
mood) in 56 patients with painful DPN (19 of whom had DPN 
with allodynia) in an open-label 3-week study (Table 1).45 
A subgroup of patients received the 5% lidocaine medicated 
plaster for an additional 5 weeks, during which taper of con-
comitant analgesic therapy was permitted; QoL benefits were 
maintained during the extended treatment period.45
Discussion
This review provides an updated summary of the published 
clinical experience with the 5% lidocaine medicated plas-
ter in a wide range of LNP conditions. The data presented 
suggest that the topical 5% lidocaine medicated plaster is 
an effective and well-tolerated treatment option in patients 
with LNP, particularly those with PHN. Indeed, numerous 
systematic reviews and international guidelines include the 
topical 5% lidocaine medicated plaster as a first-line option 
in PHN.16–26,28
In contrast, a recent systematic review/meta-analysis, 
using Grading of Recommendations Assessment, Develop-
ment, and Evaluation criteria and an assessment of number 
needed to treat (NNT) for 50% pain relief as a primary 
measure, recommends the 5% lidocaine medicated plaster 
as a second-line treatment of peripheral neuropathic pain.29 
The analysis included randomized, double-blind, placebo-
controlled studies with parallel group or crossover study 
designs that had at least ten patients per group – from these 
data, NNTs were generated. Randomized, enriched enrollment 
withdrawal trials were summarized separately. As discussed 
earlier, a number of pivotal studies of the topical 5% lido-
caine medicated plaster were enriched enrollment/withdrawal 
studies, a study design that is not conducive to inclusion/con-
sideration in meta-analyses. This is despite the fact that this 
study design is in agreement with regulatory authority (eg, US 
FDA) guidance for the approval of analgesic medications.73 
Enrichment designs can be useful to determine the success 
of a medication when compared to placebo because it allows 
for the decrease in early study dropouts caused by adverse 
events. This is particularly important in studies evaluating the 
therapeutic effect of a pain medication because the placebo 
effect is very strong in patients with pain. Furthermore, an 
enriched enrollment randomized withdrawal trial design 
allows the ability to detect desirable efficacy in a subgroup 
(and may, therefore, provide a strategy for establishing phar-
macokinetic and pharmacogenetic patient profiles), and it can 
cope with initial dose titration to mimic clinical practice,74 
with the promise of greater translational impact.75 Based 
on a comparison of results from enriched and nonenriched 
enrollment randomized withdrawal clinical trials of opioids 
in chronic noncancer pain, there also appears to be no differ-
ence in efficacy between enriched and nonenriched studies.76 
However, in the systematic review by Finnerup et al,29 one of 
the consequences of summarizing enriched enrollment studies 
separately and excluding studies in everyday clinical practice, 
which represent a large proportion of actual usage, is that 
NNTs were not determined for the 5% lidocaine medicated 
plaster, resulting in a weak recommendation for use.
The use of NNT can be criticized for several rea-
sons and can only be calculated reliably for parallel 
designed, placebo- controlled studies with comparable 
inclusion and exclusion criteria.17 As study designs for 
the 5% lidocaine medicated plaster trials were mainly 
withdrawal designs, NNT calculation was often not 
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studies with NNT data are available for the 5% lidocaine- 
medicated plaster. However, the available NNT data are in 
line with those recommended as first-line medications.17 In 
fact, in patients with various localized peripheral neuropathic 
pain syndromes, including the presence of mechanical 
allodynia, the 5% lidocaine medicated plaster as an add-on 
therapy reduced ongoing pain and allodynia with an NNT of 
4.4 (2.5–17.5).17 This is an important observation because, 
in clinical practice, multimodal therapy is considered the 
“gold standard” for the treatment of localized peripheral 
neuropathic pain.77,78 Moreover, there is a knowledge gap in 
the majority of systematic reviews and clinical guidelines, 
as they have not been able to provide recommendations for 
the treatment of individuals who fail monotherapy.16–26,28,29 In 
fact, for patients who are treated based on these guideline 
recommendations and do not experience at least 50% pain 
control, the core of the NNT concept, clinicians are currently 
using multimodal therapy with the addition of a second, third, 
or even fourth medication based on the age of the patient, 
potential for drug–drug interactions, potential for side 
effects, and opportunity to also treat comorbid conditions 
(eg, insomnia, depression, or anxiety). Consequently, the 
available guidelines have very little clinical application to 
daily practice as data on the use of multimodal therapy in the 
treatment of neuropathic pain are lacking.79 Moreover, there 
are serious flaws in performing the analysis of the studies as 
it was done for the guidelines:
1) Recommendations are mainly based on NNTs that are 
derived from the evaluation of pain based on visual analog 
scales. Clinical pain researchers have recognized that this 
evaluation may not be accurate, and patient global impres-
sion of pain improvement, psychosocial functioning, and 
activity are now utilized to fully evaluate the success of 
analgesic medication.
2) The role of anxiety and depression in amplifying pain 
symptoms is also not accounted for in these studies.
3) The placebo effect introduced by the research nurses may 
also be a potential bias in these evaluations.80–82
4) The statistical design varies from study to study. Some 
studies use the baseline evaluation carried forward, 
whereas others use the last evaluation carried forward 
when analyzing data for patients who dropped out of the 
studies. This has not been accounted for in the analysis 
done for the guidelines.
5) The maximum dose used for the majority of the medica-
tions studied varies from study to study. Thus, efficacy 
can be expected to vary as well. Clinicians are universally 
using higher doses/numbers of plasters for the treatment 
of their patients as postmarketing studies have demon-
strated increased analgesic efficacy when this approach 
is utilized.
Consequently, it is not surprising that the general find-
ings of the recent evaluation by Finnerup et al29 are largely 
reflected in a recent Cochrane review of all topical lidocaine 
preparations that found no evidence from good-quality 
randomized controlled studies to support the use of topi-
cal lidocaine to treat neuropathic pain, although individual 
studies indicated that it was effective for pain relief.83 The 
Cochrane review also noted that clinical experience supports 
the efficacy of topical lidocaine in some patients.83 Despite 
the general paucity of direct comparative data from random-
ized, controlled studies, there is a substantial body of clinical 
evidence and experience that the 5% lidocaine medicated 
plaster is a valuable and safe option in the management of 
LNP. Given the recognition that LNP is a subset of neuro-
pathic pain, a treatment algorithm was developed recently 
in order to identify patients with LNP and to guide targeted 
topical treatment with the 5% lidocaine medicated plaster.84 
Generally, the more localized the pain (ie, the area of an A4 
sheet of paper) the better the results of topical treatment.84
The 5% lidocaine medicated plaster is easy to use, 
improves patient QoL, has a good tolerability profile, and 
is associated with a lack of systemic adverse events and a 
low potential for drug–drug interactions (particularly when 
compared with systemic medications); moreover, in contrast 
to systemic therapies, there is no requirement to titrate the 
dose.15,85 These characteristics are particularly beneficial in 
elderly and medically complicated patients, including those 
with underlying comorbidities that require a polypharmacy 
management approach.85 Indeed, the most recent NeuPSIG 
recommendations also acknowledge the first-line use of the 
5% lidocaine medicated plaster as a safe and well-accepted 
option, particularly in frail or elderly individuals, where 
adverse effects or safety issues associated with systemic 
therapy are of concern.29 Extensive postmarketing surveil-
lance has confirmed the favorable safety profile of the 5% 
lidocaine medicated plaster, supporting its first-line use in 
the treatment of LNP after herpes zoster infection.15
Based on the results of randomized, controlled, and 
open-label trials and numerous studies designed to gauge 
response and experience in real-life clinical practice set-
tings, the use of the 5% lidocaine medicated plaster would 
appear to be indicated as the first step in the treatment of 
LNP as part of a multimodal approach or as a single agent. 
Recent developments with regard to the potential clinical 
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lidocaine medicated plaster warrant further investigation in 
well-controlled clinical studies.
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